Results Announced from Ph 2 SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in ovarian cancer cohort and the cervical cancer cohorts
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that results from both the ovarian cancer cohort and the cervical cancer cohort of Phase II study SKB264-II-06/MK-2870-002 of the TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870), in combination with MSD’s[1] anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA), were selected for oral presentation at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting in San Juan, Puerto Rico. The data were presented by Professor Xiaohua Wu of Fudan University Shanghai Cancer Center.
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo